Illumina Stock Slips After China Bans Imports of Gene-Sequencing Technology - Barron's
1. China banned Illumina's gene sequencer imports amid U.S. tariff retaliation. 2. Illumina's revenue from China declined by 20% in 2024. 3. Analysts maintain an Outperform rating despite tariffs and competition. 4. Illumina invests in local Chinese manufacturing to mitigate export ban effects. 5. Chinese competitors are increasing market share during Illumina's downturn.